Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Brooklyn ImmunoTherapeutics, Inc.
  6. News
  7. Summary
    BTX   US1140821000

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
0.7177 USD   -3.73%
04/21Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
AQ
04/21Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
CI
04/19BROOKLYN IMMUNOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn ImmunoTherapeutics : Maxim Starts Brooklyn ImmunoTherapeutics at Buy with $20 Price Target

10/06/2021 | 10:16am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
04/21Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Fac..
AQ
04/21Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Developme..
CI
04/19BROOKLYN IMMUNOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Financi..
AQ
04/18Brooklyn ImmunoTherapeutics Shares Slide After Company Reports Q4 Loss
MT
04/18Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Resul..
AQ
04/15BROOKLYN IMMUNOTHERAPEUTICS : Announces Fourth Quarter and Full Year 2021 Financial Result..
PU
04/15BROOKLYN IMMUNOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulat..
AQ
04/15Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended..
CI
04/15BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Co..
AQ
04/15Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Full Year Ended Dece..
CI
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -27,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,35x
Yield 2022 -
Capitalization 41,2 M 41,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 10
Free-Float 58,1%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,72 $
Average target price 4,50 $
Spread / Average Target 527%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officer
Charles Reed Cherington Director
Kevin A. D'Amour Chief Scientific Officer
Roger Sidhu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.-82.79%41
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567